I-Corps Project plan for:STTR Phase I Development of therapeutics to treat fentanyl overdose using a validated animal model

Project Summary According to the Centers for Disease Control (CDC), synthetic opioids are currently the most common cause of overdose death in the U.S, while heroin and prescription opioid deaths have decreased significantly since 2017. Despite the widespread availability of naloxone, deaths from fentanyl and fentanyl analogues (F/FA) continue to rise in parallel with increasing reports of F/FA resistance to naloxone. High doses of rapidly injected F/FA cause airway obstruction from vocal cord closure (VCC) and severe chest wall rigidity (CWR) within 2 minutes, effects that persist for up to 10 minutes and appear to be resistant to naloxone. In contrast, morphine- derived opiates (e.g. heroin) cause respiratory depression and mild muscle rigidity that is responsive to naloxone but are not known to cause VCC in humans. This suggests distinct pharmacological mechanisms underlying F/FA-induced VCC, compared to morphine-induced respiratory depression mediated by mu opioid receptors. In support of this hypothesis, off-site targets our published pharmacological data demonstrate F/FA, but not morphine or naloxone, have affinity for models of brain lipid concentrations for F/FA. Additionally, we have demonstrated in our animal model that that may regulate these F/FA-induced effects. The in vitro data include F/FA concentrations that may be physiologically relevant to humans, based on available these fentanyl-induced effects are resistant to high dose naloxone and may involve these off-site receptor targets. This preliminary data suggests the development of effective therapies for overdose require a biological model that re-conceptualizes the underlying causes of F/FA to include VCC, in addition to respiratory depression. There is currently no Federal Drug Administration development of a new class of therapeutics, specific to F/FA overdose. Under the I-Corp project, the team will seek to validate or modify its hypotheses regarding the market, target customers, and critical market need.Project Narrative Data from the Centers for Disease Control (CDC) indicate that fentanyl and fentanyl analogues (F/FA) are the most common cause of overdose deaths in the U.S., underscoring the critical need for more effective overdose treatments in the ongoing opioid crisis. Torralva Medical Therapeutics, LLC is developing an animal model that replicates the unique effects of fentanyl toxicity seen in humans and has begun target validation and development of novel formulations to effectively antagonize fentanyl doses that are routinely fatal. These formulations will solve the unmet clinical need to treat naloxone-resistant effects of F/FA overdose. The target market, customer, distribution channels, and other hypotheses on the market need and drivers will be tested under this I-Corps project.